Αρχική World News FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients... World News FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC Από Ogkologos - 25 Απριλίου, 2025 901 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... 7 Απριλίου, 2022 Keeping progress in oncology on the agenda: ESMO honours recipients of... 3 Δεκεμβρίου, 2020 Breast Cancer Patient Raising Money for 55 Women to Get Mammograms... 4 Δεκεμβρίου, 2020 Alex Trebek Gets Choked Up Seeing Contestant’s Heartfelt ‘Guess’ As Final... 14 Νοεμβρίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Understanding Genomic Correlates of Response and Acquired Resistance to FGFR Inhibitors Mom Diagnosed With Stage III Breast Cancer While Nursing Her 9-Month-Old... EMA Recommends Extension of Indications for Atezolizumab FDA Approves Cabozantinib for Differentiated Thyroid Cancer
